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Abstract
Introduction: Engagement of the homotypic cell-to-cell adhesion molecule cadherin-11 on rheumatoid arthritis (RA)
synovial fibroblasts with a chimeric molecule containing the cadherin-11 extracellular binding domain stimulated cytokine,
chemokine, and matrix metalloproteinases (MMP) release, implicating cadherin-11 signaling in RA pathogenesis.
The objective of this study was to determine if cadherin-11 extracellular domain fragments are found inside the joint
and if a physiologic synovial fibroblast cleavage pathway releases those fragments.
Methods: Cadherin-11 cleavage fragments were detected by western blot in cell media or lysates. Cleavage was
interrupted using chemical inhibitors or short-interfering RNA (siRNA) gene silencing. The amount of cadherin-11
fragments in synovial fluid was measured by western blot and ELISA.
Results: Soluble cadherin-11 extracellular fragments were detected in human synovial fluid at significantly higher
levels in RA samples compared to osteoarthritis (OA) samples. A cadherin-11 N-terminal extracellular binding
domain fragment was shed from synovial fibroblasts after ionomycin stimulation, followed by presenilin 1
(PSN1)-dependent regulated intramembrane proteolysis of the retained membrane-bound C-terminal fragments.
In addition to ionomycin-induced calcium flux, tumor necrosis factor (TNF)-α also stimulated cleavage in both
two- and three-dimensional fibroblast cultures. Although cadherin-11 extracellular domains were shed by a disintegrin
and metalloproteinase (ADAM) 10 in several cell types, a novel ADAM- and metalloproteinase-independent activity
mediated shedding in primary human fibroblasts.
Conclusions: Cadherin-11 undergoes ectodomain shedding followed by regulated intramembrane proteolysis in
synovial fibroblasts, triggered by a novel sheddase that generates extracelluar cadherin-11 fragments. Cadherin-11
fragments were enriched in RA synovial fluid, suggesting they may be a marker of synovial burden and may
function to modify cadherin-11 interactions between synovial fibroblasts.
Introduction
Synovial fibroblasts are joint stromal cells with important
roles in the normal and inflammatory synovium [1, 2]. In
the normal joint, fibroblasts remodel connective tissue
matrix and secrete the synovial fluid lubricants hyaluro-
nan and lubricin. In the inflamed joint, fibroblast hyper-
plasia contributes to pannus development, and fibroblast
activation produces many mediators that promote inflam-
mation, cartilage erosion, angiogenesis, and bone erosion.
Understanding the role of synovial fibroblasts in the
joint has been advanced by the discovery that the cell
adhesion molecule cadherin-11 specifically regulates syn-
ovial morphogenesis and synovial fibroblast function [3–8].
Cadherin-11 belongs to the cadherin family of cell-to-cell
adhesion molecules that mediate homophilic adhesion,
namely a cadherin of one type binds to cadherin of the
same type in trans on a neighboring cell through interac-
tions between their extracellular domains [9]. Cadherins
have well-described roles in organ morphogenesis and
tissue homeostasis. In the joint, cadherin-11 is critical
for synovial development. Mice genetically ablated for
cadherin-11 develop a hypoplastic synovium and, when
challenged in an inflammatory arthritis model, show both
reduced inflammation and cartilage erosion, providing
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direct in vivo evidence for the function of cadherin 11 and
fibroblasts in the normal and inflamed synovium [6].
However, cadherins do not just passively mediate cell
adhesion. Through interactions with catenins and other
signaling molecules at their cytoplasmic domain, cadherins
actively alter cell signaling pathways [10, 11]. In synovial fi-
broblasts, cell surface cadherin-11 engagement with a re-
combinant soluble form of the cadherin-11 extracellular
binding domain linked to immunoglobulin Fc tail induced
mitogen activated protein kinase and nuclear factor-κB
activation, leading to marked IL-6, chemokine, and metal-
loproteinase expression [3, 7]. Furthermore, cadherin-11
signaling acted synergistically with inflammatory cytokines
(for example, TNF-α) to amplify expression of these in-
flammatory and degradative mediators. These results sug-
gest a model where increased number and/or turnover of
cadherin-11 complexes may help to directly promote fibro-
blast activation in the synovium under inflammatory con-
ditions in rheumatoid arthritis (RA).
Cadherin turnover occurs dominantly through endoso-
mal internalization followed by either recycling back to
the cell surface or degradation in the lysosomes [12, 13].
However, an additional pathway for cadherin turnover
has been described. Some cadherins undergo stepwise
cleavage from the cell membrane by ectodomain shed-
ding followed by regulated intramembrane proteolysis, a
cleavage process with over 90 described protein substrates
[14, 15]. In this pathway, the first cleavage releases the pro-
tein ectodomain and is mediated by a variety of cell shed-
dases, mainly a disintegrin and metalloproteinase (ADAM)
family members, with the aspartyl proteases beta-secretase
(BACE)1 and BACE2 having a more limited number of
substrates. The remaining membrane stub can be further
cleaved in the transmembrane domain to release a free
cytosolic intracellular domain, a process known as regu-
lated intramembrane proteolysis. This cleavage occurs
by a limited number of intramembrane-cleaving prote-
ases (I-CLiPs). Type I proteins, like cadherins, are al-
most exclusively cleaved by γ-secretase, a multiprotein
complex containing the GXGD-type aspartyl protease
presenilin [16].
The biologic consequences of this regulated cleavage
pathway are diverse [14, 16]. Depending on the membrane
protein, cleavage may act to terminate signals from en-
gaged receptors or change the cell adhesive state. In
addition, for many molecules, the cleavage fragments have
important functions. For example, soluble ectodomains
may promote paracrine cell signaling, as seen with epi-
dermal growth factor ligand cleavage, while intracellular
domains may act as transcription factors, as seen with
Notch activation.
Cadherin cleavage may also have diverse functions, likely
depending on the cadherin, cell, and stimuli that induce
cleavage. Cadherin cleavage may help regulate the levels of
cell-to-cell contacts. For example, induction of E-cadherin
cleavage in tumor cells leads to dramatic disassembly of
cell-to-cell contacts, while blockade of cleavage through
genetic ablation of ADAM10 increases N-cadherin surface
levels on mouse fibroblasts [17, 18]. In addition, biologic
activity has been proposed for both the soluble cadherin
ectodomain and cytosolic intracellular domain [19, 20].
Soluble E-cadherin ectodomains were detected in in-
creased amounts in sera from patients with several types
of cancer and may promote cancer invasion and survival
by blocking cell adhesion and stimulating growth factor
receptor signaling [21–28]. For the released cadherin
intracellular domain, it is likely rapidly degraded by the
proteasome [16]. However, models that overexpress cad-
herin cytosolic domains have shown effects on gene tran-
scription, including E-cadherin reversal of Kaiso-mediated
gene repression by increased p120 nuclear localization
[29] and N-cadherin-mediated loss of CRE-mediated
gene transcription by increased cAMP response element-
binding protein (CREB) binding protein degradation [30].
Cadherin-11 cleavage has not been previously reported in
any mammalian system. Cadherin-11 cleavage by ADAMs
was found to contribute to Xenopus cranial neurocrest mi-
gration, although the size of the cleavage fragments was
not typical for ectodomain shedding followed by regulated
intramembrane proteolysis [31].
As a recombinant cadherin-11 extracellular domain
containing fusion protein was shown to stimulate a marked
increase in human synovial fibroblast IL-6, chemokine, and
metalloproteinase expression [3, 7], our objective was to de-
termine if cadherin-11 ectodomain shedding occurs in the
synovium and if a physiologic cleavage pathway in synovial
fibroblasts releases cadherin-11 binding domain fragments.
We found that shed soluble cadherin-11 extracellular do-
mains (sCad11) are readily detected in joint synovial fluid
and are increased in RA compared to osteoarthritis
(OA) synovial fluid. These results provide direct evi-
dence that a cadherin-11 cleavage pathway is active in
the synovium. We showed that cadherin-11 cleavage
can be stimulated by both calcium flux and TNF-α in
human synovial fibroblasts, releasing first the cadherin-
11 ectodomain and then the intracellular domain in a pre-
senilin 1 (PSN-1) dependent manner. Unexpectedly, we
found that a novel cell sheddase activity is responsible for
cadherin-11 cleavage in primary human fibroblasts. Al-
though ADAM10 mediated cadherin-11 cleavage in mouse
embryonic fibroblasts and human lung cancer cells, in-
hibitor and short-interfering RNA (siRNA) studies indi-
cate that the synovial fibroblast sheddase activity is
ADAM- and metalloproteinase-independent. In sum-
mary, this study shows that cadherin-11 cleavage is ac-
tive in the synovium and that cadherin-11 cleavage by
synovial fibroblasts has unique characteristics when
compared to other studied cell types.
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Methods
Ethical approval
Human tissues for cell-line derivation and human synovial
fluid were collected under the approval of the Institutional
Review Board of Brigham and Women’s Hospital. As all
specimens were obtained from discarded clinical speci-
mens without identifying patient information, direct pa-
tient consent was not required for this study.
Cells, media, and culture conditions
Human OA and RA synovial fibroblasts were isolated as
previously described [32] from tissues discarded after syno-
vectomy or joint replacement surgery and used experimen-
tally between passages 5 and 10. Other cell lines were
obtained as follows: ADAM-deficient mouse embryonic fi-
broblasts (MEFs) (Drs Carl Blobel and Paul Saftig), normal
human lung fibroblasts (Lonza, Allendale, NJ, USA), and
NCI-H460 lung cancer cells (ATCC, Manasses, VA, USA).
The above cells were maintained in DMEM supplemented
with 10% FBS (Gemini Bio-Products, West Sacramento,
CA, USA), 2 mM L-glutamine, 100 units/ml penicillin,
100 μg/ml streptomycin, 50 μM 2-mercaptoethanol (2-
ME), and essential and nonessential amino acids (Life
Technologies, Grand Island, NY, USA). Normal human
skin fibroblasts were obtained from discarded human fore-
skin specimens that were first digested overnight at 4°C to
remove the epithelium with a 10 mg/ml dispase II solu-
tion (Sigma-Aldrich, St. Louis, MO, USA) mixed 1:1 in
RPMI 1640 medium containing 1% bovine serum albumin,
100 units/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml
gentamicin, and 0.25 μg/ml fungizone (Life Technologies).
Fibroblasts were then isolated from the remaining dermal
fragments by digestion at 37°C in DMEM containing
2 mg/ml type IV collagenase (Worthington Biochemical,
Lakewood, NJ, USA), 0.8 mg/ml dispase (Roche Appliced
Science, Indianapolis, IN, USA), and 0.1 mg/ml DNase
I (Roche) and sequentially passaged in DMEM/F12 medium
(Life Technologies) supplemented with 10% FBS, N-2-
hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES),
L-glutamine, penicillin, streptomycin, and gentamicin. To
examine cleavage, confluent cell cultures were first starved
overnight in Opti-MEM medium (Life Technologies) before
stimulation. Human synovial micromass cultures were gen-
erated as previously described [4].
Antibodies and other reagents
The antibodies used are as follows: mouse IgG1 isotype
control (MOPC-21, Bio X Cell); anti-cadherin-11 monoclo-
nal antibody 23C6 and 3H10 [6]; anti-cadherin-11 monoclo-
nal antibody 5B2H5 and polyclonal antibody #71-7600 (Life
Technologies); anti-β-actin (AC-15, Sigma-Aldrich); anti-
presenilin 1 (D39D1) and anti-presenilin 2 (Cell Signaling
Technology, Danvers, MA, USA); anti-ADAM 10 (AB19026,
EMD Millipore, Billerica, MA, USA). Cadherin-11-Fc and
E-cadherin-Fc fusion proteins were generated as pre-
viously described [3, 33]. The other reagents used are as
follows: ionomycin (Sigma-Aldrich); human TNF-α and
platelet-derived growth factor (PDGF)-BB (R&D Systems,
Minneapolis, MN, USA); L-685,458, lactacystin, batimastat,
(TAPI-2), marimastat, and GM6001 (EMD Millipore).
Culture media was concentrated using iCON™ 9kD con-
centrators (Thermo Scientific, Grand Island, NY, USA).
siRNA transfection
Pooled siRNA against PSN1 and PSN2 and single siRNA
sequence against ADAM10 (sc-41410C) were purchased
from Santa Cruz Biotechnology. One control siRNA (also
referred to as control 1 siRNA) was purchased from
Thermo Scientific (On Target Pulse Non-targeting siRNA
#1). The sequence for control 2 siRNA is 5′ CAACAA
GAUGAAGAGCACCAAUU 3′ (synthesized by Thermo
Scientific) [7]. Primary human fibroblasts were doubly
transfected (at 0 and 48 hours) overnight with siRNA
using the lipid reagent Dharmafect 3 (Thermo Scientific).
Cells were rested for 24 hours and then serum-starved
overnight in Opti-MEM before ionomycin stimulation.
NCI-H460 cells were singly transfected with siRNA using
the lipid reagent Dharmafect 1 (Thermo Scientific) for
24 hours and then serum-starved overnight in Opti-MEM
before stimulation.
Cell lysis, western blot, and immunoprecipitation
All cells were lysed with radioimmunoprecipitation assay
(RIPA) buffer: 20 mM Tris pH 7.4, 150 mM NaCl, 0.5%
deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl
sulfate (SDS), 1 mM EDTA, 1 mM sodium orthovana-
date, 1 mM PMSF, and a mixture of protease inhibitors
(Complete, EDTA-free, Roche Applied Science). Lysates
were cleared of insoluble material by centrifugation. As
noted, lysates were immunoprecipitated with the indi-
cated antibodies using protein G sepharose beads (GE
Healthcare Life Sciences, Pittsburgh, PA, USA). Samples
were electrophoresed through polyacrylamide-SDS gels
and then transferred to Immuno-Blot polyvinylidene fluo-
ride (PVDF) membranes (Bio-Rad, Hercules, CA, USA).
Membranes were blocked in phosphate-buffered saline
containing 0.05% Tween and 5% bovine serum albumin
and then incubated with antibodies against the target pro-
teins. After washing, the membranes were incubated with
horseradish peroxidase-conjugated anti-mouse IgG or anti-
rabbit IgG antibodies (Jackson Immuno Research, West
Grove, PA, USA) before detection with a chemiluminescent
substrate. Full images for all cropped blots are provided in
Additional file 1 and Additional file 2.
Synovial fluid studies
For immunoprecipitation studies, synovial fluid (200 μl)
was digested with 25 μg/ml hyaluronidase (Sigma Aldrich)
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for 15 minutes at room temperature. Prior to immunopre-
cipitation and western blot analysis, synovial fluid was
pre-cleared with protein G-sepharose beads and human
immunoglobulins and albumin were then removed using a
high-affinity spin column (Thermo Scientific). To detect
sCad11 by ELISA, high-binding 96-well plates (Costar,
Tewksbury, MA, USA) were coated with anti-cadherin-11
monoclonal antibody 3H10 (4 μg/ml) and then blocked in
HBS Ca (20 mM Hepes, 137 mM NaCl, 3 mM KCl, 1 mM
CaCl, pH 7.4) with 1% bovine serum albumin. Undiluted
synovial fluid was then incubated in the wells for 2 hours
at room temperature. After washing, biotinylated anti-
cadherin-11 antibody 23C6 (2 μg/ml) was added for
2 hours at room temperature. Binding of cadherin-11
extracellular fragments was detected by incubation with a
streptavidin-alkaline phosphatase followed by colorimetric
detection with p-nitrophenyl phosphate substrate.
Statistical analysis
For pooled analyses, n refers to the number of independ-
ent experiments, with an experiment containing the re-
sults from one donor-derived fibroblast population. The
number of unique donor-derived fibroblasts used is also
indicated in these experiments. Often independent ex-
periments were conducted more than once with a given
fibroblast using different passages. All statistical analyses
were calculated using GraphPad Prism software. All
mean pixel density measurements from western analysis
were calculated using Image J software.
Results
We previously observed that a recombinant cadherin-11
extracellular domain Fc protein activated multiple signaling
pathways in synovial fibroblasts, inducing expression of IL-
6 and other mediators important in RA pathogenesis (see
Fig. 1a, and previous studies [3, 7]). These studies sug-
gest that soluble cleavage fragments containing cadherin-
11 extracellular domain, if present in the synovium, may
have biologic activity. Therefore, we determined if intact,
soluble cadherin-11 extracellular domains (sCad11) could
be isolated from patient synovial fluid specimens. We first
demonstrated by immunoprecipitation that an approxi-
mately 75kD-band with a size consistent for sCad11 was
detected in synovial fluid specimens (Fig. 1b). We then de-
veloped an ELISA to detect sCad11 from patient samples.
In this assay, sCad11 is first captured with an extracellular
cadherin11 epitope antibody and then detected with a sep-
arate biotinylated extracellular cadherin11 epitope anti-
body that does not interfere with epitope binding by the
first antibody. This assay specifically detects cadherin-11
extracellular domains, but not ectodomains from another
cadherin, E-cadherin (Fig. 1c). Using this assay, we deter-
mined the sCad11 levels in synovial fluid obtained from
both OA and RA patients (Fig. 1d). Although sCad11 was
detected in both, sCad11 levels were significantly
increased in RA samples, likely reflecting the increased
amount of synovial tissue present in RA. These results pro-
vide direct evidence supporting activity of a cadherin-11
cleavage pathway in vivo.
As cadherin-11 is expression is restricted to fibroblasts
in the synovium, we then determined if a physiologic
cadherin-11 cleavage pathway generating such fragments
is active in these cells. As ectodomain shedding followed
by regulated intramembrane proteolysis has been de-
scribed for several other cadherins [20], we hypothesized
that a sequential two-step cleavage pathway also occurs
for cadherin-11 (Fig. 2a). In this model, a cell sheddase
cleaves cadherin-11 near the extracellular membrane face
to release a soluble N-terminal fragment containing the
intact binding domain (sCad11) and a membrane-tethered
fragment C-terminal fragment 1 (CTF1). CTF1 may then
be processed by PSN in the γ-secretase complex to release
the cadherin-11 intracellular domain into the cytosol, re-
ferred to as C-terminal fragment 2 (CTF2). CTF2 may
then be further degraded by the proteasome.
Our initial experiments investigated if a cadherin-11
cleavage pathway was active in primary human synovial
fibroblasts. As calcium flux is a well-described stimulus
for ectodomain shedding, human RA synovial fibroblasts
were treated with ionomycin to induce cadherin-11 cleav-
age. Ionomycin stimulation led to a time-dependent loss of
full-length (FL) cadherin-11 from cell lysates as measured
by western blot (Fig. 2b). Analysis with an anti-cadherin-11
antibody directed against an intracellular epitope (5B2H5)
showed correlated accumulation of a cadherin-11 fragment
whose molecular weight was consistent with that predicted
for CTF1 (approximately 33 kD). This fragment was not
detected by an anti-cadherin-11 antibody directed against
an extracellular epitope (3H10). Loss of cell surface
cadherin-11 after ionomycin treatment was confirmed by
flow cytometry (Fig. 2c). Compared to untreated cells,
ionomycin-stimulated synovial fibroblasts showed marked
loss of cadherin-11 staining, even though the expression of
another cell surface molecule, major histocompatibility
complex (MHC) class I, was preserved. Consistent with a
cleavage mechanism where cell surface expression is lost
through ectodomain shedding, an extracellular cadherin-
11 fragment was also detected in the synovial fibroblast
culture media. Western blot analysis of concentrated cul-
ture media from ionomycin-stimulated synovial fibroblasts
showed that the extracellular 3H10 antibody detected an
approximately 75-kD species, the size of which is consist-
ent with the intact cadherin-11 ectodomain (Fig. 2d). Cell
lysates showed parallel intracellular CTF1 accumulation
after ionomycin stimulation. In addition, immunoprecipi-
tation of unstimulated culture media with one extracellu-
lar domain anti-cadherin-11 antibody (23C6) followed by
western blot with another (3H10) also detected a 75kD
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species, indicating that a low level of constitutive
cadherin-11 shedding is present in synovial fibroblasts
(Fig. 2E). Similarly, although CTF1 was readily detected
in ionomycin-stimulated cells, no statistically significant
detection of CTF1 over background was seen in un-
stimulated cells by western blot analysis using standard
exposure times (Fig. 2f, Additional file 3). However, with
longer exposures, constitutive CTF1 generation was visual-
ized. Cadherin-11 cleavage was not unique to RA synovial
fibroblasts, as a similar intracellular cleavage fragment was
also detected in OA fibroblasts after ionomycin stimulation
(Additional file 4).
Although ionomycin potently stimulates cadherin-11
cleavage, we wished to determine if signals more physio-
logic to the inflamed RA synovium also might drive
cleavage. We found that TNF-α treatment increased
cadherin-11 cleavage in synovial fibroblast monolayers,
although not as strongly as ionomycin (Fig. 3a-b). In
comparison, platelet-derived growth factor (PDGF)-BB,
a potent driver of cadherin-11 endocytosis and cell migra-
tion, did not induce any cadherin-11 cleavage. We then
examined cadherin-11 cleavage in a three-dimensional
synovial culture micromass to better mimic synovial archi-
tecture. In this system, we found that TNF-α also induced
cleavage (Fig. 3c). These data, taken together, suggest that
TNF-α likely provides an inflammatory signal that helps
increase cadherin-11 cleavage in the RA synovium.
Having identified a putative post-cleavage cadherin-11
intracellular fragment with a molecular size consistent
for CTF1, proteasome and γ-secretase activity was then
targeted to confirm its identity by showing this fragment
undergoes regulated intramembrane proteolysis to gen-
erate CTF2. First, synovial fibroblasts were treated with
the γ-secretase inhibitor L-685,458 to reduce cleavage of
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IL-6 release was then measured by ELISA. Similar results were previously
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fluid samples from OA patients were immunoprecipitated with a
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CTF1 to CTF2. Inhibitor-treated cells showed a dose-
dependent increase in CTF1 after ionomycin stimulation
(Fig. 4a-b), suggesting that CTF1 is further processed by
the γ-secretase complex, as predicted in our cleavage
model (Fig. 2a).
Next, as CTF2 is generally rapidly degraded by the
proteasome, synovial fibroblasts were treated with the
proteasome inhibitor lactacystin to enhance CTF2 detec-
tion. Lactacystin-treated cells showed a dose-dependent
accumulation of a low molecular fragment with a size
consistent for CTF2 (Fig. 4c-d). In this experiment,
CTF1 and CTF2 were detected in both unstimulated and
ionomycin-stimulated fibroblasts. Detection of CTF2 re-
quires long exposure times. As shown earlier (Fig. 2f),
long exposure times also detect a level of constitutive
cleavage in unstimulated cells.
Finally, the catalytic component of γ-secretase, the
aspartyl protease PSN, was silenced using siRNAs directed
against the two homologous proteins, PSN1 and PSN2
(Fig. 4e-f). PSN1-silenced cells showed impaired ability to
generate CTF2, strongly pointing to PSN1 as a critical me-
diator of cadherin-11 intramembrane cleavage. In con-
trast, PSN2 silencing increased CTF2 accumulation, with
CTF2 detected even without stimulation (Fig. 4e-f), indi-
cating PSN2 does not have a catalytic role in generating
cadherin-11 CTF2. It is possible that absence of PSN2
increases PSN1-complex interactions with cadherin-11,
promoting CTF2 generation. Taken together, these experi-
ments demonstrate that γ-secretase mediates cadherin-11
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a C-terminal fragment 1 (CTF1) and an extracellular domain fragment
(sCad11). Then CTF1 is cleaved near the intracellular plasma membrane,
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transcription. (b) Lysates from RA synovial fibroblasts stimulated with
5 μM ionomycin as indicated were analyzed by western blot using
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intracellular (5B2H5) epitopes (FL, full length cadherin-11). (c) Surface
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cleavage, confirming cadherin-11 is a substrate for regu-
lated intramembrane proteolysis in synovial fibroblasts.
After finding that cadherin-11 is cleaved by γ-secretase,
we sought to identify which protease mediates the first
cleavage step, generation of sCad11 and CTF1 from the
full-length protein. The most likely candidate was an
ADAM family member. ADAMs are the dominant cell
sheddases in regulated intramembrane proteolysis for
multiple proteins on various cell types [34, 35]. ADAM10,
in particular, has been reported to cleave E-cadherin,
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N-cadherin, and VE-cadherin [18, 22, 29, 36–38] while
ADAM15 may also contribute to E-cadherin cleavage
[28]. Several ADAMs, including ADAM10, are expressed
on synovial fibroblasts [39–41], suggesting ADAMs are
candidates to mediate cadherin-11 cleavage.
To examine if ADAM proteins cleave cadherin-11, we
used MEFs genetically deficient in both ADAM9 and
ADAM15 or ADAM10 alone. Compared to ADAM9/
ADAM15-deficient cells, generation of cadherin-11 CTF1
after ionomycin was completely absent in ADAM10-
deficient cells (Fig. 5a), implicating ADAM10 as a sheddase
for cadherin-11 cleavage. We then used siRNA to silence
ADAM10 in human synovial fibroblasts. Surprisingly, des-
pite efficient ADAM10 silencing, the absence of ADAM10
did not block cadherin-11 cleavage in synovial fibroblasts
(Fig. 5b-c), and additional silencing of ADAM9, ADAM12,
and ADAM15 also had no effect (data not shown). We
then tested the effect of ADAM10 silencing in several add-
itional human cell types. ADAM10 silencing in the lung
cancer cells H460 inhibited generation of CTF1, but had
no effect in two additional primary human fibroblast lines
derived from skin and lung, respectively (Fig. 5b-c). These
results suggested that although ADAM10 contributes to
cadherin-11 cleavage in MEFs and human epithelial carcin-
oma, it does not in primary human fibroblasts obtained
from various tissue sites.
As the majority of cell sheddase activity is reported to
be mediated by metalloproteinases (for example, ADAMs
and matrix metalloproteinases (MMPs)), we decided to use
chemical inhibitors to examine if cadherin-11 cleavage is
mediated by metalloproteinase activity (Fig. 5d). MEFs,
H460 cells, synovial fibroblasts, lung fibroblasts, and skin
fibroblasts were pretreated with the broad spectrum metal-
loproteinase inhibitor batimastat before ionomycin stimu-
lation. As expected, CTF1 generation was completely
inhibited by batimastat in both MEFs and H460 cells. Re-
markably, batimastat did not block cadherin-11 cleavage in
primary synovial, lung, or skin fibroblasts, even at a dose
100-fold higher than the dose needed to inhibit cleavage in
H460 cells (Additional file 5). Additional metalloproteinase
Fig. 5 Comparison of sheddase activity in mouse embryonic fibroblasts (MEFs), NCI-H460, and primary human fibroblasts. (a) Lysates from MEFs
genetically deficient in a disintegrin and metalloproteinase (ADAM10 −/−) or (b) from NCI-H460, synovial fibroblasts, lung fibroblasts, or skin
fibroblasts transfected with control or ADAM10 siRNA were analyzed for cadherin-11 cleavage in the presence or absence of ionomycin
(representative of at least three experiments, fibroblasts (Fb). ADAM10 siRNA silencing was confirmed by western blot and β-actin levels
confirmed equal protein loading. (c) C-terminal fragment 1 (CTF1) and ADAM10 expression was measured by calculating the mean pixel intensity
of CTF1 and ADAM10 bands across several experiments in control and ADAM10 siRNA treated cells for the indicated cell types (H460, n = 3;
*P = 0.049 by paired t-test; lung and skin fibroblasts, n = 3; synovial fibroblasts, n = 6, five separate rheumatoid arthritis (RA) lines; error bars reflect
standard error of mean). ADAM10 silencing efficiency (mean+/−standard deviation): H460 cells, 77.0 + 5.67%; synovial fibroblasts, 70.2+/−25.5%;
lung fibroblast, 85.0+/−8.04%; skin fibroblasts, 58.8+/−7.77%. (d) Cell lysates from indicated cells treated overnight with the metalloproteinase
inhibitor batimastat (10 μM) or appropriate dimethyl sulfoxide (DMSO) vehicle control were assayed for cadherin-11 cleavage in the presence and
absence of ionomycin stimulation (representative of at least three experiments per cell type). Equal protein loading was confirmed by β-actin staining
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inhibitors (TAPI-2, marimastat, and GM6001) also did not
block cleavage in synovial fibroblasts (Additional file 6),
pointing to an unexpected, non-ADAM sheddase mediat-
ing cadherin-11 cleavage in primary human fibroblasts. Al-
though the identity of the fibroblast sheddase remains to
be determined, these results highlight that shedding of a
cell surface protein may occur by very different mecha-
nisms in distinct cell types.
Discussion
We previously demonstrated that a recombinant soluble
form of the extracellular cadherin-11 binding domain
(cadherin-11-Fc) was highly active biologically and stimu-
lated synovial fibroblasts to produce chemokines, cyto-
kines, and MMPs in synergy with inflammatory cytokines,
pointing to an important role for cadherin-11 signaling in
RA disease pathogenesis [3, 7]. Although cadherin signal-
ing may be induced through formation of new cell-to-cell
contacts [11], it is also possible that soluble cadherin-11
extracellular domains shed from synovial fibroblasts may
also contribute to those interactions. Cadherin-11 shedding
from synovial fibroblasts seemed likely, given that protein
ectodomain shedding has been described for several cad-
herins in other cell types [17, 18, 29, 30, 36]. In this study,
we detected shed cadherin-11 ectodomains in joint syn-
ovial fluid, directly demonstrating that a cadherin-11 cleav-
age pathway is active in the synovium. We then showed
that cadherin-11 undergoes protein ectodomain shedding
followed by PSN-dependent regulated intramembrane pro-
teolysis in synovial fibroblasts and discovered several novel
features of that cleavage.
First, we showed that after ectodomain shedding,
cadherin-11 is processed by the γ-secretase complex
(Fig. 4). This complex is composed of four integral
membrane proteins in 1:1:1:1 stoichiometry: presenilin,
nicastrin, anterior-pharynx defective-1 (APH-1), and pre-
senilin enhancer-2. Although enzymatic activity is medi-
ated by PSN, the other components contribute to complex
stability and substrate recognition [16, 42]. The PSN fam-
ily contains two homologous proteins, PSN1 and PSN2,
with approximately 67% amino acid identity. In addition,
APH-1 also has two homologues, one of which has two
splice variants. Therefore, up to six different γ-secretase
forms may exist within a cell. This study contributes to
emerging evidence showing that these distinct γ-secretase
complexes may have unique substrate specificities and cel-
lular locations. We demonstrated that PSN1, not PSN2,
mediates cadherin-11 CTF1 to CTF2 processing. In fact,
as PSN2 silencing increased CTF2 cleavage, PSN2 may act
to inhibit PSN1 cleavage, possibly by binding to a subset
of cadherin complexes. Whether PSN1-dependent cleav-
age is unique to cadherin-11 in synovial fibroblasts or is
a more general feature of cadherin cleavage remains to
be determined.
Ectodomain shedding is the rate-limiting step in regu-
lated intramembrane proteolysis, and the dominant cell
sheddases are ADAM family members [15, 35]. Several
ADAMs, especially ADAM 10, are known to cleave other
cadherins [18, 22, 29, 36–38]. In this study, we found that
ADAM 10 can cleave cadherin-11 on MEFs and a lung
cancer cell line, but show it does not cleave cadherin-11
on several types of primary human fibroblasts, despite de-
tectable ADAM10 expression in these cells. In fact, using
several chemical inhibitors, we found that the sheddase is
likely not a metalloproteinase, excluding a role in cleavage
for other ADAMs or MMPs. The identity of the cadherin-
11 sheddase on human fibroblasts is currently not known.
One possible candidate is a member of the BACE family
of aspartyl proteases, another important sheddase family
[15, 43]. However, BACE proteins currently have a very
limited number of identified substrates, and no activity
against cadherins has been reported. Another possibility
includes the serine proteases kallikrein and plasmin, both
of which release the E-cadherin extracellular domain in
recombinant protein systems [24, 26]. However, these
studies did not show shedding in a cell system or link this
shedding to subsequent processing by γ-secretase.
Further investigations are needed to identify the
cadherin-11 sheddase activity and understand why
ADAM10 does not mediate cleavage despite detectable
expression on synovial fibroblasts. However, some predic-
tions about the cleavage region can be made by examining
the ionomycin-induced metalloproteinase cleavage sites
identified for E-cadherin [17] and N-cadherin [37]. For both
of these cadherins, cleavage occurs very proximally, within
10 amino acid of the transmembrane domain. For E-
cadherin, cleavage occurs between Proline700 and Valine701,
while for N-cadherin, cleavage involves Isoleucine715.
Sequence alignment of these regions with cadherin-11
shows the likely area of cleavage to generate cadherin-
11 ectodomains (Additional file 7). We do not know
whether or not metalloproteinase-mediated cleavage
in H460 cells shares the same cleavage site as non-
metalloproteinase-mediated cleavage in primary fibro-
blasts. However, given the similar size of shed cadherin-11
ectomains and CTF1 in these two cell types, we would
predict that the cleavage sites, if not identical, would be
very close to each other.
Although stimulating fibroblasts in vitro with ionomycin,
a potent inducer of calcium flux, is helpful in studying
cleavage mechanisms, it remains an artificial system. As the
major mechanism of cadherin turnover is through the
endocytic pathway, we wished to determine if cadherin-11
cleavage occurs in vivo in the synovium. Using both west-
ern blot and ELISA analyses, we detected the soluble extra-
cellular cadherin-11 domain in synovial fluid specimens,
providing strong evidence for an active cadherin-11 cleav-
age pathway in the synovium (Fig. 1). Furthermore, the
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amount of cleavage fragments was significantly enhanced in
RA synovial fluid compared to OA, suggesting that cleavage
may correlate with the amount of synovial tissue or inflam-
matory signals. Indeed, we found that the inflammatory
cytokine, TNF-α, also induced cleavage, both in standard
monolayer cultures and in a three-dimensional culture sys-
tem that more closely mimics synovial lining structure.
Although cadherin-11 cleavage occurs in the syno-
vium, the functional consequences of that cleavage are
not known. One possibility is that cadherin-11 cleavage
disrupts cell-to-cell contacts, potentially altering the ad-
hesive state of synovial fibroblasts. Indeed, stimulating
E-cadherin cleavage disrupts cell contact in A431 epi-
dermoid carcinoma cells [17], while inhibiting ADAM
protease activity in MEFs and human umbilical vein endo-
thelial cells increased surface N-cadherin and VE-cadherin
levels, respectively [18, 36]. However, how much or when
cadherin-11 proteolysis contributes to cadherin-11 turn-
over is uncertain, as the major pathway for cadherin con-
tact remodeling is generally accepted to occur through
endocytosis [13].
Nevertheless, a strong case can be made that the shed
cadherin extracellular domains may have biologic activ-
ity [19, 21]. In tumor studies, cadherin extracellular
domains promote cell migration and invasion likely by
inhibiting cadherin cell adhesion interactions [24–27].
However, soluble forms of E-cadherin have also been
shown to directly bind to and stimulate the growth fac-
tor receptors, epidermal growth factor receptor (EGFR),
Her2, and Her3 [22, 23, 28], activating cell signaling
pathways. Our work showed that a recombinant chimeric
molecule containing the cadherin-11 extracellular domain
stimulated pro-inflammatory mediator production in syn-
ovial fibroblasts [3, 7], suggesting that shed cadherin-11
promotes synovial activation in RA. However, in vitro acti-
vation of synovial fibroblasts requires substantially higher
concentrations of cad11Fc compared to the concentra-
tions of shed cadherin-11 detected in synovial fluid. On
the other hand, synovial fluid levels are unlikely to re-
flect the true local concentration of shed cadherin-11 in
the synovial lining. Further investigation to determine
the biologic function of shed cadherin-11 in the syno-
vium may need to model the effect of shed cadherin-11
in a three dimensional system that mimics synovial lin-
ing architecture.
Another possibility is that the intracellular domain
fragment released into the cytosol, CTF-2, also may have
biologic activity. CTF2 retains the ability to bind β-catenin
and p120 catenin, both of which can localize to the nu-
cleus to affect gene transcription [10]. In fact, E-cadherin
CTF2 overexpression in MDCK cells resulted in increased
transport of p120 catenin to the nucleus, allowing p120 to
relieve Kaiso-mediated gene repression [29]. In addition, N-
cadherin CTF2 overexpression in mouse L cells increased
degradation of CREB-binding protein by the proteosome,
reducing CRE-mediated gene transcription [30]. Atlhough
it is intriguing to consider CTF2 as a signaling molecule,
rapid proteosomal degradation of CTF2 in the absence of
an overexpression system makes it more difficult to assign
biologic activity to cadherin CTF2 fragments. It remains
to be determined if cadherin-11 CTF2 has any functional
activity in synovial fibroblasts.
Conclusion
We previously found that a cadherin-11 extracellular do-
main fusion protein stimulated synovial fibroblasts to pro-
duce inflammatory and degradative mediators important in
RA pathogenesis. In this study, we present evidence that
cadherin-11 extracellular domains are shed from synovial
fibroblasts by a novel, non-metalloproteinase sheddase and
then further cleaved by regulated intramembrane proteoly-
sis to release the cytoplasmic domain. Furthermore, shed
cadherin-11 extracellular domains were readily isolated
from patient synovial fluid and were significantly enriched
in RA compared to OA samples, indicating that this cleav-
age pathway is active in the synovium. We propose that
shed cadherin-11 may help promote RA pathogenesis by
acting in synergy with inflammatory cytokines to promote
synovial fibroblast activation.
Additional files
Additional file 1: Figure. S1. Complete gels for the cropped images in
Fig. 1b, Fig. 2e, Fig. 3c, and Fig. 4a-c are provided in this file.
Additional file 2: Figure. S2. Complete gels for the cropped images in
Fig. 5 are provided in this file.
Additional file 3: Figure. S3. Constitutive and induced C-terminal
fragment 1 (CTF1) generation in rheumatoid arthritis (RA) synovial fibroblasts.
Cell lysates from RA synovial fibroblasts stimulated with or without 5 μM
ionomycin for one hour were analyzed for cadherin-11 cleavage by western
blot. Two exposure times of the western blot are shown- standard and long.
Representative figure for the pooled data shown in Fig. 2f.
Additional file 4: Figure. S4. Cadherin-11 cleavage in osteoarthritis
(OA) synovial fibroblasts. Cell lysates from an OA synovial fibroblast line
stimulated with or without 5 μM ionomycin for one hour were analyzed
for cadherin-11 cleavage by western blot.
Additional file 5: Figure. S5. Effect of increasing doses of the
metalloproteinase inhibitor batimastat in NCI-H460 cells and synovial
fibroblasts. (a) NCI-H460 cells or (b) rheumatoid arthritis (RA) synovial
fibroblasts were treated overnight without or with increasing concentrations
of batimastat and then left unstimulated or stimulated with 5 μM ionomycin
for one hour before lysis. Cell lysates were analyzed for cadherin-11 cleavage
by western blot. Equal protein loading was confirmed by β-actin staining.
Additional file 6: Figure. S6. Effect of several metalloproteinase
inhibitors in mouse embryonic fibroblasts (MEFs) or synovial fibroblasts. (a)
MEFs or rheumatoid arthritis (RA) synovial fibroblasts were left untreated or
treated overnight with 30 μM batimastat, 100 μM TNF-α protease inhibitor 2
(TAPI-2), or dimethyl sulfoxide (DMSO) vehicle control. Ionomycin (5 μM) or
vehicle control was then added for one hour before cell lysis. Cell lysates
were analyzed for cadherin-11 cleavage by western blot. Equal protein
loading was confirmed by β-actin staining. (b) RA synovial fibroblasts were
left untreated or pretreated with marimastat, GM6001, or DMSO vehicle
control before addition of ionomcyin or vehicle control. Cell lysates were
then analyzed for cadherin-11 cleavage by western blot.
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Additional file 7: Figure. S7. Comparison of cadherin-11 sequence to
known metalloproteinase cleavage sites in other cadherins. E-cadherin,
N-cadherin, and cadherin-11 extracellular domain amino acid sequences
just proximal to the transmembrane domain are aligned. Known amino
acids acid involved in metalloproteinase-mediated ectodomain shedding
are indicated by bold, underlined typeface.
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